AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 26-A-05-061.01
We recommend that CMS work with sponsors, as appropriate, to ensure sponsors' claims for Part D compounded drugs are accurately reported on PDE…
The publisher's file lists October 16, 2026 as the date the next update was expected. That date has passed. This is the publisher's own date field, not a finding that anyone missed a deadline.
The recommendation, in the publisher's words
We recommend that CMS work with sponsors, as appropriate, to ensure sponsors' claims for Part D compounded drugs are accurately reported on PDE records consistent with CMS guidance.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- April 17, 2026
- Report
- CMS Has Limited Oversight of Selected Compounded Drugs Prescribed to Medicare Part D Enrollees (A-05-21-00008) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Overdue (as recorded by the publisher)
- Next update expected
- October 16, 2026 (publisher's date)
- Publisher topics
- Departmental Operational Issues, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
2 more, of which 2 are open in the publisher's file.
- We recommend that CMS provide guidance to sponsors on enhancing their oversight of compounded drugs containing controlled substances and gabapentin, such as ensuring their quality…HHS OIG 26-A-05-061.02 · issued Apr 17, 2026Open Unimplemented
- We recommend that CMS provide guidance to sponsors regarding monitoring active pharmaceutical ingredients in bulk powder form used in compound drugs.HHS OIG 26-A-05-061.03 · issued Apr 17, 2026Open Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.